For the private sector spin, the graphs were interesting. You can see that when the pan-Canadian pharmaceutical negotiations started, on the public sector side the expenditure begins ro drop or slow down, whereas the private sector expenditure continues to grow. I think the understanding of how the negotiation of pricing happens in Canada, and how we are situated...I think we're second right now in the G7 for the cost of drugs.
You could look at the G7 costing and move us more to the median or average pricing. Are there similar models you could use to arrive at a target cost of a national pharmaceutical program?